A Novel Grape-Derived Prebiotic Selectively Enhances Abundance and Metabolic Activity of Butyrate-Producing Bacteria in Faecal Samples

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) patients have different faecal microbiota profiles compared to healthy controls. Prebiotics intake influences intestinal microbiota composition which in turn influence the growth of short-chain fatty acids (SCFA) producing bacteria....

Full description

Bibliographic Details
Authors: Oliver, Lia, Ramió Pujol, Sara, Amoedo Cibeira, Joan, Malagón Rodríguez, Marta, Serrano, Marta, Bahí, Anna, Lluansí Salis, Aleix, Torrealba, Leyanira, Busquets Casals, David, Pardo, Laura, Serra Pagès, Mariona, Aldeguer i Manté, Xavier, Garcia-Gil, L. J.
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10256/22063
Online Access:http://hdl.handle.net/10256/22063
Access Level:Open access
Keyword:Intestins -- Microbiologia
Intestines -- Microbiology
Prebiòtics
Prebiotics
Intestins -- Inflamació
Inflammatory bowel diseases
Còlon irritable
Irritable colon
Description
Summary:Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) patients have different faecal microbiota profiles compared to healthy controls. Prebiotics intake influences intestinal microbiota composition which in turn influence the growth of short-chain fatty acids (SCFA) producing bacteria. This study aimed to evaluate the capacity of Previpect, a new prebiotic obtained from grapes fibre, to balance the dysbiosis found in patients with intestinal disorders. This was achieved through the analysis of specific bacterial markers and SCFA production using an in vitro fermentation system and comparing the obtained results with those obtained with other commercial prebiotics. Fresh faecal samples from patients with IBD (N = 6), IBS (N = 3), and control subjects (N = 6) were used. Previpect showed high fermentative ability enabling the growth of butyrate producing bacteria and increasing SCFA concentration up to 2.5-fold. Previpect is a promising prebiotic which may be used as a therapeutic strategy towards promotion of intestinal microbiota restoration, microbial healing, and as a preventive supplement for healthy individuals

Similar Items